Clinical Trial Detail

NCT ID NCT02275533
Title Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.